

1.	<p>Treatment & Condition</p> <p>Ocrelizumab for treating primary progressive multiple sclerosis.</p>																		
2.	<p>Associated appraisal body & Summary of ruling</p> <p>NICE Technology Appraisal guidance TA585 (June 2019)</p> <p>Ocrelizumab (Ocrevus[®]) is recommended, within its marketing authorisation, as an option for treating early primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in adults. It is recommended only if the company provides it according to the commercial arrangement.</p>																		
3.	<p>Number of people in Northern Ireland expected to take up service/therapy</p> <table border="1" data-bbox="261 846 1445 1146"> <thead> <tr> <th colspan="6" data-bbox="261 846 1445 994">Estimated number of people in Northern Ireland having ocrelizumab for primary progressive MS</th> </tr> <tr> <th data-bbox="261 994 590 1034"></th> <th data-bbox="590 994 761 1034">2019/20</th> <th data-bbox="761 994 932 1034">2020/21</th> <th data-bbox="932 994 1102 1034">2021/22</th> <th data-bbox="1102 994 1273 1034">2022/23</th> <th data-bbox="1273 994 1445 1034">2023/24</th> </tr> </thead> <tbody> <tr> <td data-bbox="261 1034 590 1146">Population having ocrelizumab each year</td> <td data-bbox="590 1034 761 1146">17</td> <td data-bbox="761 1034 932 1146">38</td> <td data-bbox="932 1034 1102 1146">48</td> <td data-bbox="1102 1034 1273 1146">57</td> <td data-bbox="1273 1034 1445 1146">76</td> </tr> </tbody> </table>	Estimated number of people in Northern Ireland having ocrelizumab for primary progressive MS							2019/20	2020/21	2021/22	2022/23	2023/24	Population having ocrelizumab each year	17	38	48	57	76
Estimated number of people in Northern Ireland having ocrelizumab for primary progressive MS																			
	2019/20	2020/21	2021/22	2022/23	2023/24														
Population having ocrelizumab each year	17	38	48	57	76														
4.	<p>Patient Access Scheme Availability</p> <p>(<u>Yes</u>/No)</p> <p>The company (Roche) has a commercial arrangement. This makes ocrelizumab available to the NHS with a discount. The size of the discount is commercial in confidence.</p>																		
5.	<p>Infrastructure Requirements</p> <p>Infrastructure requirements for the delivery of all disease modifying therapies (DMTs) for MS are reviewed annually as part of routine commissioning arrangements for supporting growth in the provision of these therapies.</p>																		
6.	<p>Expected implementation period</p> <p>There is no impediment to immediate implementation for new patients.</p>																		
7.	<p>Commissioning arrangements</p> <p>This drug will be formally commissioned by HSCB/PHA via the Specialist Services Commissioning Team initially on a cost per case basis.</p>																		

8.	Monitoring arrangements The HSC Board has robust arrangements in place for the monthly monitoring of all DMTs (patient numbers, costs and waiting times). This regime will be included within the monitoring information. Monitoring returns are reviewed by the Specialist Services Commissioning Team each month.
9.	DoH (NI) Legislative/Policy Caveats This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case. The Rural Needs Act NI 2016 has been considered and this guidance, which is purely of a technical nature, is not regarded as falling within the scope of the act.